BUY DOMS Industries Limited — ICICI Securities
byICICI SecuritiesHorizon: NA (inferred 1 year)4 Nov 2026via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
3 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · same horizon·4 Nov · 3d ago
Long-term trend bearish — 200-day average falling over the past quarter
Technicals · trend·6 Nov · yesterday
DOMS Industries Q2 Results: Flood damage, exceptional expense drag profit down to 36%
NewsCnbc-Tv18·2 Nov · 4d ago
DOMS Industries reported Q2 FY27 revenue growth of 17.6% YoY, but EBITDA declined 16.8% and PAT fell 37% due to exceptional expenses from flood-related damages and higher input costs.
BSE · Company Update·2 Nov · 4d ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on DOMS Industries
- BUY — Axis Securities4 Nov 2026 · ~1 year · target ₹2,090 · Target hit
- BUY — Nuvama Wealth4 Nov 2026 · ~1 year · target ₹2,773 · Active
- BUY — Prabhudas Lilladher7 Oct 2026 · ~1 year · target ₹2,783 · Active
- BUY — ICICI Securities5 Aug 2026 · ~1 year · target ₹2,600 · Active
- BUY — Prabhudas Lilladher4 Aug 2026 · ~1 year · target ₹2,703 · Active
More from ICICI Securities
- BUY ICICI Bank5 Nov 2026 · ~1 year · target ₹1,800 · Active
- BUY Stylam Industries5 Nov 2026 · ~1 year · target ₹3,750 · Active
- BUY Emcure Pharmaceuticals5 Nov 2026 · ~1 year · target ₹2,560 · Active
- BUY Saregama India5 Nov 2026 · ~1 year · target ₹740 · Active
- BUY Procter & Gamble Health4 Nov 2026 · ~1 year · target ₹6,680 · Active

